ImmunityBio Secures Exclusive U.S. Rights for Tokyo-172 BCG, Expanding Product Pipeline
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio has entered into an exclusive development and supply agreement with Japan BCG Laboratory, securing U.S. rights for the Tokyo-172 strain of BCG. This pact grants ImmunityBio exclusive rights to develop, clinically test, seek regulatory approval, and then purchase, import, sell, and distribute the product in the U.S. for 10 years following FDA approval. The agreement is financially favorable as no payments are due before regulatory approval. This strategic partnership expands ImmunityBio's product pipeline and future revenue potential in the U.S. market, building on the positive Q1 2026 financial results reported earlier this month. Investors will now watch for updates on the clinical development and regulatory progress of Tokyo-172 BCG.
At the time of this announcement, IBRX was trading at $8.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.